Recently, there has been increasing attention for a potential role of plasmin in the treatment of disorders associated with spontaneous von Willebrand factor (VWF)–platelet aggregation, such as thrombotic thrombocytopenic purpura (TTP).3, 4This review provides an overview of the literature on the effects of plasmin on VWF and platelets. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.